Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) inspected Raleigh Plant, North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the company, established for manufacturing Inhalers, Dermatology and Transdermal products, from 24 March 2025 to 10 April 2025. At the end of inspection, form 483 was issued with a total of 11 observations.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.